Arcturus Therapeutics Holdings Inc. (ARCT) — 10-Q Filings

10-Q Filings (6)

• Arcturus Q3 Revenue Plunges, Net Loss Widens Amid R&D Cuts — Nov 12, 2025 Risk: high
  Arcturus Therapeutics Holdings Inc. reported a significant decrease in revenue and an increased net loss for the three and nine months ended September 30, 2025,
• Arcturus Swings to Profit on Soaring Collaboration Revenue — Aug 11, 2025 Risk: medium
  Arcturus Therapeutics Holdings Inc. reported a significant increase in collaboration revenue to $104.9 million for the three months ended June 30, 2025, up from
• Arcturus Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  Arcturus Therapeutics Holdings Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities,
• Arcturus Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and operational updates. Key
• Arcturus Therapeutics Q2 Revenue Surges on Collaboration Deals — Aug 5, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. filed its 10-Q for the period ending June 30, 2024. The company reported collaboration revenue of $10.2 million for the thre
• Arcturus Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. (ARCT) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Arcturus Therapeutics Holdings Inc. filed a 10-Q report

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX